Literature DB >> 2227106

Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate.

S M Brichard1, C J Bailey, J C Henquin.   

Abstract

The trace element vanadium exerts insulinlike effects in vitro and decreases hyperglycemia in insulin-deficient animals. This study examined whether vanadate can improve glucose homeostasis in genetically obese hyperglycemic insulin-resistant ob/ob mice, which present metabolic abnormalities similar to those of human non-insulin-dependent diabetes. Sodium orthovanadate (0.3 mg/ml) was administered for 7 wk in H2O. Vanadate treatment induced a fall in fed and fasted plasma glucose and insulin levels and improved tolerance to oral glucose; the stimulated glucose area was decreased by 65%, and an early peak of insulin secretion was restored. During an intravenous glucose tolerance test, the glucose disappearance rate was twofold higher in vanadate-treated mice, and the reappearance of a significant insulin response was also observed. Moreover, vanadate produced a twofold increase in hepatic glycogen content and prevented the exhaustion of pancreatic insulin stores. The hypoglycemic response to exogenous insulin was similar in control and treated mice. In vitro experiments showed that basal glucose oxidation by hemidiaphragms was 32% higher in vanadate-treated mice than in controls, although stimulation by insulin was similar in both groups. In conclusion, oral vanadate caused a marked and sustained improvement of glucose homeostasis in diabetic insulin-resistant mice by exerting an insulinlike effect on peripheral tissues and apparently preventing the exhaustion of pancreatic insulin stores.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227106     DOI: 10.2337/diab.39.11.1326

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

Review 1.  Anti-diabetic and toxic effects of vanadium compounds.

Authors:  A K Srivastava
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

2.  In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals.

Authors:  R L Khandelwal; S Pugazhenthi
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 3.  Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling.

Authors:  I G Fantus; G Deragon; R Lai; S Tang
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

4.  In vivo effects of peroxovanadium compounds in BB rats.

Authors:  J F Yale; C Vigeant; C Nardolillo; Q Chu; J Z Yu; A Shaver; B I Posner
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 5.  In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus.

Authors:  A B Goldfine; D C Simonson; F Folli; M E Patti; C R Kahn
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

6.  Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents.

Authors:  D C Crans; M Mahroof-Tahir; A D Keramidas
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 7.  Increased potency of vanadium using organic ligands.

Authors:  J H McNeill; V G Yuen; S Dai; C Orvig
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 8.  Effects of vanadate on the expression of genes involved in fuel homeostasis in animal models of Type I and Type II diabetes.

Authors:  S M Brichard
Journal:  Mol Cell Biochem       Date:  1995 Dec 6-20       Impact factor: 3.396

Review 9.  Vanadium and diabetes.

Authors:  P Poucheret; S Verma; M D Grynpas; J H McNeill
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

10.  Non-insulin-like action of sodium orthovanadate in the isolated perfused liver of fed, non-diabetic rats.

Authors:  M Roden; K Liener; C Fürnsinn; M Prskavec; P Nowotny; I Steffan; H Vierhapper; W Waldhäusl
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.